**4. Conclusion**

Eflornithine concentrations were measurable at 24 h, with peak concentrations in plasma of 5.3 ng/ml after cream and 3.8 ng/ml after composition application (p < 0.001). After combined use of Eflornithine and Armenicum, the average time to reach the maximum concentration of Eflornithine is observed, which increased from 2 h to 3.3 h. The area under the Eflornithine plasma concentration versus time curve was decreased after composition application by 25%. Eflornithine was eliminated from plasma with a mean terminal half-life of 11.6 hours without statistically significant difference after cream and composition application.

Thus, it can be assumed that the combined use of Eflornithine and Armenicum in the form of a composition allows for maintaining the optimal concentration of two anti-inflammatory compounds at the site of application for a long time, which can improve their pharmacological effect compared to the separate use of Eflornithine cream.
